Everything tagged "ipo" across the TickerSpark archives.
Medline is growing quickly, but heavy debt and margin pressure keep the stock in disciplined Buy territory. The report sees solid medium-term upside, with fair value above the recent trading price.
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) is expected to list on 2026-08-07 at a price range of $16.00 to $18.00 per share. The company is offering 16,000,000 shares, with a disclosed market cap of $331.2 million. The bull case is a differentiated non-opioid pain platform; the bear case is a clinical-stage biotech with no revenue, rising losses, and a long road to approval.
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) is expected to list on 2026-08-07 at a price range of $15.00 to $17.00 per share. The company is offering 7,812,500 shares, implying a market cap of $152,734,375 if priced at the midpoint assumptions provided. The bull case is a focused oncology pipeline with named clinical programs and a seasoned drug-discovery team. The bear case is straightforward: no product revenue, rising losses, and a going-concern warning if it cannot raise more capital.
Arc Group Securities Acquisition I is expected to list on NASDAQ on 2026-08-04. The company has not disclosed a price range yet, and the IPO is for 10,500,000 units with a $105,000,000 base offering size. Bull case: a focused sponsor team and a clean trust structure; bear case: it is still a blank-check company with no target announced.
Eos Energy Enterprises, Inc. is expected to list on NASDAQ on 2026-08-04, but the price range has not been disclosed. The company is already public, so the key event to watch is its latest equity financing and how investors respond to the Frontier-linked capital plan. Bulls will focus on rapid revenue growth and a large backlog; bears will focus on dilution, execution, and funding dependence.
Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) is expected to list on 2026-08-04, but the price range has not been disclosed. The company is coming to market through an all-stock reverse merger with Galera Therapeutics rather than a traditional IPO. Bull case: a differentiated cell-therapy platform with strong strategic backing; bear case: no disclosed pricing, no commercial revenue, and heavy clinical risk.
First Trust Exchange-Traded Fund VIII (FFLX) is expected to list on NYSE on 2026-08-10, but the price range has not been disclosed. This looks less like a classic IPO and more like an ETF trust listing with creation/redemption mechanics. Watch whether the fund’s product lineup and fee structure can attract assets in a crowded ETF market.
Braveheart Bio (NASDAQ: BRVE) is expected to list on 2026-08-06 at a price range of $15.00 to $17.00 per share. The company is offering 18,750,000 shares, with a disclosed market cap of $366,562,500. The bull case is a differentiated oral HCM drug with Phase 3 ambitions; the bear case is that this is still a pre-revenue biotech with heavy clinical, financing, and competition risk.
Atento S.A. is expected to list on NASDAQ on 2026-08-05 in a 12,500,000-share offering priced at $15.00 to $17.00 per share. The implied market cap is $244,375,000 if priced at the midpoint. The bull case is a scaled CRM/BPO platform with AI and nearshore delivery; the bear case is that the company already appears to be a long-established public issuer, so investors should watch closely for confirmation of what is actually being offered.
Columbus Circle Cap Corp. Iii (NASDAQ: CCCT) is expected to list on 2026-07-31, but the price range has not been disclosed yet. This is a SPAC, so the real question is not near-term revenue but whether the team can find a credible target before the clock runs out. The setup favors investors who want sponsor pedigree and a Europe/North America deal pipeline, while the main bear case is classic SPAC dilution and no target in hand.
Carillon Series Trust is expected to list on 2026-08-03 on the NYSE, but the price range has not been disclosed. The key question is not a classic IPO valuation debate — it is whether this fund platform’s ETF conversion story is compelling enough to attract attention. Bull case: the structure taps the ongoing shift from mutual funds to ETFs. Bear case: this is not a traditional operating-company IPO, so the usual growth and profitability metrics are not available.
Southern Cross Acquisition I Corp. Rights (NASDAQ: NCOOR) is expected to list on 2026-07-31, but the price range has not been disclosed yet. This is a SPAC rights offering tied to a blank-check company, so the key question is what kind of deal the sponsor can eventually bring to market. The setup favors investors who are comfortable with SPAC optionality; the main bear case is the usual one: no target, no operating business, and dilution risk.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime